Kun Xu

Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C

Andreas Weiss, Edwige Lorthiois, Louise Barys et al. · Cancer Discovery · 2022 · 130 citations · Full text

Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors.

Irene Braña, Geoffrey I. Shapiro, Melissa L. Johnson et al. · Journal of Clinical Oncology · 2021 · 67 citations

Tumor Biology, Molecular Pharmacology, Dose Finding Study +14

Yanghe Decoction Suppresses the Experimental Autoimmune Thyroiditis in Rats by Improving NLRP3 Inflammasome and Immune Dysregulation

Bing’e Ma, Dexuan Chen, Yangjing Liu et al. · Frontiers in Pharmacology · 2021 · 29 citations · Full text

Abstract CT033: KontRASt-01: A phase Ib/II, dose-escalation study of JDQ443 in patients (pts) with advanced, KRAS G12C-mutated solid tumors

Daniel Shao-Weng Tan, Toshio Shimizu, Benjamin Solomon et al. · Cancer Research · 2022 · 17 citations

Immunology, Pathology, Abstract Ct033 +17

Phase I Clinical Study of Edaravone in Healthy Chinese Volunteers

Hao Li, Kun Xu, Yongqing Wang et al. · Drugs in R&D · 2012 · 16 citations · Full text